Abstract | OBJECTIVE: The aim of the study was to investigate a dose-intensified, preoperative chemotherapy with 3 cycles (cy) of epirubicin 60 mg/m2, ifosfamide 5 g/m2 with mesna 5 g/m2, biweekly with G-CSF 5 micrograms/kg ( filgrastim), in terms of toxicity, clinical and pathological remission rates and changes of immunohistochemical characteristics (ER, PR, c-erbB2, p53) during chemotherapy of inoperable patients (pt) with poor prognosis (locally advanced (LABC, 9 pt), inflammatory breast cancer (IBC, 12 pt) and M0. PATIENTS AND METHODS: RESULTS: Primary toxicity (T): grade 3 alopecia (21 pt), grade 3-4 leucopenia (7 cy), grade 1-2 leucopenia (26 cy), grade 1-2 anemia (61 cy), grade 1-2 neurocortical T (13 cy), grade 1-2 neurosensory T (7 cy), grade 1 cardiac toxicity (1 pt). ORR: 65% (CR: 0 pt, PR: 13 pt, NC: 8 pt). The grades of histological regression were: 0: 14 pt, 1: 6 pt, 2: 0 pt, 3: 1 pt. No significant correlation was observed between the clinical response and the histological regression (Fischer's exact test). The immunohistochemical expression of tumor characteristics did not change significantly during preoperative chemotherapy (Wilcoxon test). 81% of the pt were disease-free after a median follow-up of 20 months (7-26). CONCLUSION:
|
Authors | J U Blohmer, S Paepke, L Kissner, D Elling, B Fleige, Y Grineisen, W Lichtenegger |
Journal | Zentralblatt fur Gynakologie
(Zentralbl Gynakol)
Vol. 121
Issue 11
Pg. 522-5
( 1999)
ISSN: 0044-4197 [Print] Germany |
PMID | 10612219
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Protective Agents
- Recombinant Proteins
- Tamoxifen
- Granulocyte Colony-Stimulating Factor
- Epirubicin
- Mesna
- Paclitaxel
- Filgrastim
- Ifosfamide
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Breast Neoplasms
(drug therapy, pathology, radiotherapy, surgery)
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Epirubicin
(administration & dosage, adverse effects)
- Female
- Filgrastim
- Granulocyte Colony-Stimulating Factor
(therapeutic use)
- Humans
- Ifosfamide
(administration & dosage, adverse effects)
- Immunohistochemistry
- Mastectomy
- Mesna
(therapeutic use)
- Middle Aged
- Neoplasm Staging
- Paclitaxel
(administration & dosage, adverse effects)
- Pilot Projects
- Protective Agents
(therapeutic use)
- Recombinant Proteins
- Survival Analysis
- Tamoxifen
(administration & dosage, adverse effects)
- Treatment Outcome
|